Portfolio company
COUR Pharmaceuticals
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
6 investors
Sectors
Digital Health
About
This company develops antigen-specific therapies to treat autoimmune diseases by reprogramming the immune system to restore self-tolerance.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.